TD Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-44,021
Closed -$6.72M 1291
2026
Q1
$6.72M Buy
44,021
+11,586
+36% +$1.78M 0.01% 736
2025
Q4
$4.47M Buy
32,435
+7,620
+31% +$998K ﹤0.01% 819
2025
Q3
$3.18M Buy
24,815
+4,115
+20% +$502K ﹤0.01% 872
2025
Q2
$2.5M Buy
20,700
+3,271
+19% +$369K ﹤0.01% 883
2025
Q1
$1.94M Buy
17,429
+1,374
+9% +$146K ﹤0.01% 969
2024
Q4
$1.56M Sell
16,055
-52
-0.3% -$5.54K ﹤0.01% 1058
2024
Q3
$1.86M Sell
16,107
-318
-2% -$36.1K ﹤0.01% 1063
2024
Q2
$1.75M Sell
16,425
-35,531
-68% -$3.57M ﹤0.01% 1044
2024
Q1
$5.03M Sell
51,956
-3,140
-6% -$322K ﹤0.01% 780
2023
Q4
$5.56M Buy
55,096
+41,815
+315% +$4.04M 0.01% 737
2023
Q3
$1.35M Buy
13,281
+67
+0.5% +$6.8K ﹤0.01% 1066
2023
Q2
$1.33M Sell
13,214
-556
-4% -$55.6K ﹤0.01% 1065
2023
Q1
$1.27M Sell
13,770
-719
-5% -$62.8K ﹤0.01% 1093
2022
Q4
$1.31M Sell
14,489
-118
-0.8% -$9.94K ﹤0.01% 1091
2022
Q3
$1.12M Buy
14,607
+1,478
+11% +$123K ﹤0.01% 1159
2022
Q2
$1.11M Buy
13,129
+24
+0.2% +$2.11K ﹤0.01% 1167
2022
Q1
$1.15M Sell
13,105
-280
-2% -$24.2K ﹤0.01% 1208
2021
Q4
$1.17M Sell
13,385
-66
-0.5% -$5.48K ﹤0.01% 1250
2021
Q3
$1.1M Sell
13,451
-32,478
-71% -$2.92M ﹤0.01% 1228
2021
Q2
$4.24M Buy
45,929
+469
+1% +$41.8K ﹤0.01% 872
2021
Q1
$3.89M Buy
45,460
+2,862
+7% +$257K ﹤0.01% 900
2020
Q4
$4.02M Sell
42,598
-13,575
-24% -$1.19M ﹤0.01% 850
2020
Q3
$4.88M Sell
56,173
-96,799
-63% -$8.39M 0.01% 711
2020
Q2
$13.4M Sell
152,972
-17,915
-10% -$1.55M 0.02% 449
2020
Q1
$14.1M Buy
170,887
+9,987
+6% +$891K 0.02% 401
2019
Q4
$15.2M Sell
160,900
-1,017
-0.6% -$91.3K 0.02% 443
2019
Q3
$14.1M Sell
161,917
-1,987
-1% -$178K 0.02% 437
2019
Q2
$15M Sell
163,904
-23,968
-13% -$2.03M 0.02% 424
2019
Q1
$16.2M Sell
187,872
-33,756
-15% -$2.71M 0.02% 402
2018
Q4
$17M Sell
221,628
-6,970
-3% -$543K 0.03% 379
2018
Q3
$17.6M Buy
228,598
+19,528
+9% +$1.44M 0.03% 415
2018
Q2
$14.2M Buy
209,070
+22,877
+12% +$1.58M 0.02% 456
2018
Q1
$13.5M Buy
186,193
+11,110
+6% +$846K 0.02% 457
2017
Q4
$13.2M Buy
175,083
+19,164
+12% +$1.45M 0.02% 465
2017
Q3
$12M Buy
155,919
+20,963
+16% +$1.58M 0.02% 480
2017
Q2
$10.1M Buy
134,956
+48,688
+56% +$3.45M 0.02% 520
2017
Q1
$5.74M Buy
86,268
+43,925
+104% +$2.93M 0.01% 654
2016
Q4
$2.76M Sell
42,343
-3,030
-7% -$197K ﹤0.01% 799
2016
Q3
$3.21M Buy
45,373
+4,502
+11% +$328K 0.01% 787
2016
Q2
$3.02M Buy
40,871
+2,571
+7% +$178K 0.01% 783
2016
Q1
$2.49M Sell
38,300
-24,034
-39% -$1.64M ﹤0.01% 808
2015
Q4
$4.81M Buy
62,334
+3,253
+6% +$258K 0.01% 668
2015
Q3
$4.87M Sell
59,081
-709
-1% -$63.1K 0.01% 638
2015
Q2
$5.27M Sell
59,790
-4,463
-7% -$409K 0.01% 652
2015
Q1
$5.68M Sell
64,253
-30,392
-32% -$2.7M 0.01% 633
2014
Q4
$7.86M Buy
94,645
+35,729
+61% +$2.96M 0.01% 546
2014
Q3
$4.97M Sell
58,916
-20,559
-26% -$1.66M 0.01% 642
2014
Q2
$6.45M Sell
79,475
-17,542
-18% -$1.38M 0.01% 578
2014
Q1
$7.39M Buy
97,017
+14,896
+18% +$1.09M 0.01% 544
2013
Q4
$5.92M Buy
82,121
+2,016
+3% +$140K 0.01% 584
2013
Q3
$5.51M Sell
80,105
-18,610
-19% -$1.23M 0.01% 583
2013
Q2
$6.25M Buy
+98,715
New +$6.42M 0.01% 521

Other funds holding NVS

TD Asset Management's NVS Position: Q2 2026 in Review

TD Asset Management sold out of Novartis (NVS) in Q2 2026, closing a stake of 44,021 shares — an estimated $6.72M sold.

TD Asset Management first reported a position in NVS in Q2 2013 and held it in 52 quarters. The position peaked at $17.6M in Q3 2018. 1,377 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • TD Asset Management reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • TD Asset Management sold 44,021 Novartis shares in Q2 2026, an estimated $6.72M.
  • TD Asset Management first reported a position in Novartis in Q2 2013 and held it in 52 quarters.
  • TD Asset Management's Novartis position peaked at $17.6M in Q3 2018.
  • 1,377 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.